All Data
Expert and Agile CDMO Partner for tailor-made solutions.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Aerami
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Details:
Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-gene therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $106.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 01, 2021
Details:
The new funding will allow Tenaya to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARO-ANG3
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-ANG3
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
By inhibiting ANGPTL3, Arrowhead’s investigational ARO-ANG3 is designed to reduce triglycerides and decrease LDL cholesterol in patients with mixed dyslipidemia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VERVE-101
Therapeutic Area: Cardiology/Vascular Diseases Product Name: VERVE-101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Wellington Management Company
Deal Size: $94.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 19, 2021
Details:
Proceeds from the financing will be used to advance the company’s pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VERVE-101
Therapeutic Area: Cardiology/Vascular Diseases Product Name: VERVE-101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
The new data demonstrate that in vivo base editing of the PCSK9 gene in the liver of non-human primates resulted in durable and consistent lowering of blood LDL-C and blood PCSK9 protein levels following a single course of treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zofin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zofin
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Organicell Regenerative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 20, 2020
Details:
Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: JanOne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 06, 2020
Details:
CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INS-3001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
U.S. patent number covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MAT9001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: BTIG
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: IPO January 09, 2020
Details:
Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development for its product candidates, namely MAT9001, and its lipid nano-crystal (“LNC”) platform delivery technology
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
